<DOC>
	<DOCNO>NCT00741598</DOCNO>
	<brief_summary>This study examine whether extended release galantamine , drug approve Food Drug Administration reduce cognitive impairment people Alzheimer 's disease , perform function stable people bipolar disorder .</brief_summary>
	<brief_title>Efficacy Safety Galantamine Improving Dysfunction People With Bipolar Disorder</brief_title>
	<detailed_description>Approximately 2.6 % Americans age 18 old , 5.7 million people , suffer bipolar disorder . The manic depressive episode associate bipolar disorder prevent normal functioning individual disorder , functional impairment occur even bipolar disorder remission . Previous research indicate impairment stable individual bipolar disorder link neurocognitive deficit , problem memory attention . The drug extend release galantamine increase level acetylcholine , neurotransmitter important memory , available brain . This drug already approve FDA treat neurocognitive impairment Alzheimer 's disease patient . This study examine whether administer drug individual bipolar disorder remission also reduce neurocognitive deficit improve quality life . The study also examine safety drug use obsessive-compulsive disorder population . Participation study last 18 week involve six study visit . Each first two visit include 2 hour clinical , physical , self-report test , first screen second establish physical mental health baseline measurement . Participants randomly assign receive either galantamine placebo daily 16 week , provide enough assign pill last next visit . Half hour visit Weeks 4 , 8 , 12 consist psychological self-report test interview , clinical assessment side effect drug , determination examine doctor participant whether increase , decrease , maintain level drug . Participants also give enough drug last next visit . The final visit , Week 16 , last 2 hour consist test administer baseline visit addition neuropsychological test administer screen visit . The full range test measure physical health , verbal memory , mental flexibility , attention , life impairment , life satisfaction .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>DSMIV diagnosis Bipolar I disorder Bipolar II disorder A baseline HamiltonD 17 score less 10 screen visit A baseline Young Mania Rating Scale ( YMRS ) score less 10 screen visit No acute episodes depression mania previous 12 week Score 17 high Massachusetts General Hospital ( MGH ) Cognitive Physical Functioning Questionnaire Treated psychiatric medication , alone combination , minimal , mild moderate cognitive burden [ determine score less 3.5 MGH Cognitive Impact Psychotropic Medications Scale ( CIPMS ) . Able understand English DSMIV diagnosis Bipolar NOS , Cyclothymia , Schizoaffective Bipolar type . Meets DSMIV criterion acute manic , depressive , mixed bipolar episode meet full criterion 2 consecutive week within past 12 week prior assessment Treated psychiatric medication large effect cognition ( determine MGH Cognitive Impact Psychotropic Medications Scale score 4.0 ) Pregnant woman woman child bear potential use medically accept mean contraception ( defined oral contraceptive pill implant , condom , diaphragm , spermicide , IUD , s/p tubal ligation , partner vasectomy ) Serious suicide homicide risk Unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease . History seizure disorder , brain injury , know neurological disease ( multiple sclerosis , degenerative disease ALS , Parkinson disease movement disorder , etc ) The following DSMIV diagnosis : 1 ) organic mental disorder ; 2 ) diagnosis dementia ; 3 ) substance use disorder , include alcohol , active within last year ; 4 ) schizophrenia ; 5 ) delusional disorder ; 6 ) psychotic disorder elsewhere classify ; 7 ) schizoaffective disorder ; 8 ) major depressive disorder ; 9 ) acute bereavement ; 10 ) severe borderline antisocial personality disorder Presence mood congruent mood incongruent psychotic feature Clinical laboratory evidence hypothyroidism History multiple adverse drug reaction , allergy galantamine AChEIs Current use , use within last week , exclude drug ( psychotropic medication central nervous system ( CNS ) active drug ) Taken investigational psychotropic drug within last year Had electroconvulsive therapy ( ECT ) within 6 month precede enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>